ID   LICR-HN2 R10.3
AC   CVCL_LI54
DR   Wikidata; Q54902513
RX   PubMed=26269754;
CC   Selected for resistance to: DrugBank; DB00002; Cetuximab (Erbitux).
CC   Derived from site: In situ; Larynx; UBERON=UBERON_0001737.
DI   NCIt; C4044; Laryngeal squamous cell carcinoma
DI   ORDO; Orphanet_494550; Squamous cell carcinoma of the larynx
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_8125 ! HN-2
SX   Male
AG   49Y
CA   Cancer cell line
DT   Created: 15-11-17; Last updated: 29-06-23; Version: 7
//
RX   PubMed=26269754; PMCID=PMC4529614;
RA   Boeckx C., Blockx L., Op de Beeck K., Limame R., Van Camp G.,
RA   Peeters M., Vermorken J.B., Specenier P., Wouters A., Baay M.,
RA   Lardon F.;
RT   "Establishment and characterization of cetuximab resistant head and
RT   neck squamous cell carcinoma cell lines: focus on the contribution of
RT   the AP-1 transcription factor.";
RL   Am. J. Cancer Res. 5:1921-1938(2015).
//